AUTHORS
Shirong Liu, PhD, Xia Liu, MD2, Amanda Kofides, MSc3, John Hatcher, PhD4, Yuntong Liu5, Hao Sun, MD, PhD6, Nickolas Tsakmaklis7, Alberto Guijosa, MD8, Jinhua Wang, PhD9, Maria Luisa Guerrera, MD10, Christopher Patterson, MBA, MPH11, Zachary R Hunter, PhD12, Shayna Sarosiek, MD13, Jorge J Castillo, MD14, Praful Gokhale I15, Sara Buhrlage, PhD16, Steven Treon, MD, PhD17
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Harvard Medical School, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Harvard Medical School, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Activating MYD88 mutations drive pro-survival signaling through signaling channels that include HCK directed BTK signaling (Yang et al, Blood 2016). BTK-inhibitors are active in many mutated MYD88 driven malignancies, but resistance commonly arises through acquired BTK mutations that target covalent (BTKCys481Ser, BTKCys481Arg, BTKCys481Tyr, BTKAla428Asp, BTKLeu528Trp), non-covalent (BTKVal416Leu, BTKAla428Asp, BTKThr474Leu, BTKLeu528Trp, BTKMet437Arg) and proteolysis targeting chimera (BTKAla428Asp). The downstream signaling cascades related to BTK for many of these acquired mutations remains to be clarified but may involve alternative signaling cascades mediated by SRC family members that include the SRC family member HCK (Dhami et al, Sci. Sign. 2022)
We therefore developed a comprehensive panel of mutant BTK (BTKCys481Ser , BTKVal416Leu, BTKAla428Asp , BTKMet437Arg , BTKThr474Leu , BTKLeu528Trp ) MYD88L265P mutated BCWM.1 and TMD8 lymphoma cell models to delineate their respective BTK signaling cascades. We then characterized mutation associated pro-survival signaling by Western blot analysis. In BCWM.1 and TMD8 cells expressing BTKAla428Asp, BTKLeu528Trp and BTKLeu528Trp, as well as TMD8 cells expressing BTKMet437Arg loss of BTKY223 phosphorylation was observed indicating a loss of dependence on canonical BTK kinase activation. Furthermore, expression of HCK and/or its homologue LYN were enhanced in these BTK kinase dead mutant expressing cells. To clarify the role of these SRC family members, we performed knockdown studies in TMD8 cells expressing the pan-BTK-inhibitor resistant BTKAla428Asp mutation which triggered robust apoptosis. Given the dependence of BTK kinase dead mutants on SRC family members, we assessed the activity of the novel HCK/LYN/BTK PROTAC, DFCI-002-06 (Hatcher et al, J. Med Chem. 2026) in BCWM.1 and TMD8 cells expressing BTK kinase dead mutants. DFCI-002-06 effectively suppressed phosphorylation at BTKTyr551, induced degradation of HCK, LYN and BTK, and suppressed downstream PLCγ2 and ERK signaling. These effects translated into potent anti-proliferative and pro-apoptotic activity in vitro and significant tumor growth inhibition in vivo in BTKAla428Asp and BTKLeu528Trp expressing TMD8 xenografted mice.
These findings show that acquired resistance to BTK targeting agents is driven by BTK mutation specific compensatory signaling that involves SRC family members. The novel HCK/LYN/BTK PROTAC DFCI-002-06 induced degradation of HCK, LYN and BTK in mutated kinase dead BTK expressing cells and induced potent ant-tumor activity, thereby providing a framework for the clinical development of this agent in BTK-inhibitor resistant MYD88 mutated B-cell malignancies.
DISCLOSURES
Shirong Liu, PhD: No relevant conflicts of interest to declare.